<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Fennec Pharmaceuticals Inc.

    Fennec Pharmaceuticals Inc.

    Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...

    Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...

    Filing Type:    PU
    Pulmatrix, Inc.

    Pulmatrix, Inc.

    Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...

    Pulmatrix is a clinical stage biopharmaceutical...

    Filing Type:    PU
    TherapeuticsMD, Inc.

    TherapeuticsMD, Inc.

    TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed...

    TherapeuticsMD, Inc. is an innovative pharmaceu...

    Filing Type:    PU
    Scholar Rock Holding Corporation

    Scholar Rock Holding Corporation

    Scholar Rock is a biopharmaceutical company focused on the discovery and developme...

    Scholar Rock is a biopharmaceutical company foc...

    Filing Type:    PU
    Ovid Therapeutics Inc.

    Ovid Therapeutics Inc.

    Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing...

    Ovid Therapeutics is a biopharmaceutical compan...

    Filing Type:    PU
    Caladrius Biosciences, Inc.

    Caladrius Biosciences, Inc.

    Caladrius is a clinical-stage biopharmaceutical company committed to the developme...

    Caladrius is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Conatus Pharmaceuticals Inc.

    Conatus Pharmaceuticals Inc.

    Conatus Pharmaceuticals is a biotechnology company focused on the development and ...

    Conatus Pharmaceuticals is a biotechnology comp...

    Filing Type:    PU
    Galectin Therapeutics Inc.

    Galectin Therapeutics Inc.

    Galectin Therapeutics is a biotechnology company focused on discovery and developm...

    Galectin Therapeutics is a biotechnology compan...

    Filing Type:    PU
    GENFIT S.A.

    GENFIT S.A.

    GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...

    GENFIT is a late-stage biopharmaceutical compan...

    Filing Type:    PU
    Edesa Biotech, Inc.

    Edesa Biotech, Inc.

    Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...

    Edesa Biotech Inc. is a clinical-stage biopharm...

    Filing Type:    PU
    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...

    Ritter Pharmaceuticals, Inc. develops novel the...

    Filing Type:    PU
    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...

    Protagonist Therapeutics is a clinical stage bi...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.